Table 1.

Demographics of RRMM patients treated with bispecific antibodies.

Agent Name	Target	Author, Year	Clinical Trial	Evaluable Patients/Sample Size	Median Age	Male Sex, %	Median Line of Treatment
Teclistamab [19]	BCMA-CD3	Touzeau et al., 2022	NCT04557098	38	63.5	63%	6
Teclistamab [20]	BCMA-CD3	Martinez-Lopez et al., 2022	NCT03145181	165	64	58%	5
Teclistamab+ Daratumumab [21]	BCMA-CD3+ anti-CD38	Otero et al., 2022	NCT04108195	46	67	48%	6
Teclistamab + Daratumumab + Lenalidomide [22]	BCMA-CD3+ anti-CD38+ IMiD	Searle at al., 2022	NCT04722146	32	62	87.5%	2
Elranatamab [23]	BCMA-CD3	Raje et al., 2022	NCT03269136	55	64	NR	5
Elranatamab [24]	BCMA-CD3	Bahlis et al., 2022	NCT04649359	123	68	55.3%	5
Elranatamab + Daratumumab [25]	BCMA-CD3+ anti-CD38	Grosicki et al., 2022	NCT05020236	28	68	NR	5
Pavuratamab (AMG-701) [26]	BCMA-CD3	Harrison et al., 2020	NCT03287908	75	63	NR	6
Pacanalotamab (AMG-420) [27]	BCMA-CD3	Topp et al., 2022	NCT02514239	42	65	64%	7
RO7297089 [28]	BCMA-CD16a	Plesner et al., 2021	NCT04434469	21	63	NR	8
ABBV-383 [29]	BCMA-CD3	D’Souza et al., 2022	NCT03933735	124	68	55%	5
REGN5458 [30]	BCMA-CD3	Bumma et al., 2022	NCT03761108	167	64	49%	6
WVT078 [31]	BCMA-CD3	Raab et al., 2022	NCT04123418	33	NR	NR	2
Talquetamab [32]	GPRC5D-CD3	Chari et al., 2022	NCT03399799/ NCT04634552	143	67	NR	5
Talquetamab+ Daratumumab [33]	GPRC5D-CD3+ anti-CD38	Donk et al., 2022	NCT04108195	46	65	52%	5
RG6234 [34]	GPRC5D-CD3	Carlo-Stella et al., 2022	NCT04557150	C1: 51 C2: 54	C1: 62 C2: 64	NR	C1:5 C2:4
Cevostamab [35]	FcRH5-CD3	Lesokhin et al., 2022	NCT03275103	16	66.5	NR	6
ISB 1342 [36]	CD38-CD3	Mohan et al., 2022	NCT03309111	24	67	63%	6

NR—not recorded, C1—cohort 1, C2—cohort 2, and IMiD—immunomodulatory agent.